Nanomedicine News

RSS

Merck Serono to Provide Strategic Support for Auxogyn's Early Embryo Viability Assessment Test

Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test. Under the terms of the agreement, Merck Serono will provide strategic, scientific and medical support in the development and commercialization of the Eeva™ Test.

20 Oct 2012

VNT Paclitaxel Nanocarrier-Based Drug Coated Balloon Technology Performs Well in In Vivo Tests

Vascular Nanotransfer Technologies (“VNT”), an emerging medical technology company, announced today that large animal model in vivo tests of its paclitaxel nanocarrier-based Drug Coated Balloon (“DCB”) achieved tissue levels comparable to devices with proven clinical efficacy.

20 Oct 2012

Multi-Functional, NIR Responsive Gold Nanorods for Targeted Delivery of Chemotherapy Drugs

Excitement around the potential for targeted nanoparticles (NPs) that can be controlled by stimulus outside of the body for cancer therapy has been growing over the past few years. More specifically, there has been considerable attention around near-infrared (NIR) light as an ideal method to stimulate nanoparticles from outside the body.

19 Oct 2012

Scientists Determine 3-D Structure of Transcription Initiation Complex

An team of Rutgers University scientists led by Richard H. Ebright and Eddy Arnold has determined the three-dimensional structure of the transcription initiation complex, the key intermediate in the process by which cells read out genetic information in DNA.

19 Oct 2012

INNI Appoints TAU to Lead Consortium on Nanomedicines for Personalized Theranostics

Tel Aviv University has been appointed by the Israel National Nanotechnology Initiative (INNI) to lead a consortium on "Nanomedicines for Personalized Theranostics," a combined system of diagnostics and therapeutic treatments. This consortium of 11 laboratories will be dedicated to developing nano-sized drug delivery systems for the detection and treatment of various diseases. Eight of the labs are TAU-led, with additional participation from Hebrew University Jerusalem, Bar-Ilan University and Ben Gurion University of the Negev.

19 Oct 2012

Novavax Announces Encouraging Clinical Trial Results for Nanoparticle-Based Pandemic Influenza Vaccine

Novavax, Inc. today reported positive top-line results from two Phase 1 clinical trials of its A/H5N1 avian influenza vaccine candidate administered alone or with either one of two undisclosed adjuvants.

18 Oct 2012

New Nanoparticle-Based Treatment Holds Potential for Traumatic Brain Injury

A potential new treatment for traumatic brain injury (TBI), which affects thousands of soldiers, auto accident victims, athletes and others each year, has shown promise in laboratory research, scientists are reporting.

18 Oct 2012

Novavax Begins Phase 1 Clinical Trial of Nanoparticle-Based RSV Vaccine Candidate

Novavax, today announced that enrollment has begun in a Phase 1 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adults 60 years of age and older.

From Novavax Inc. 16 Oct 2012

Nanotechnology-Based Delivery System for Sustained Release of Drugs

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr. Paul Ashton, will discuss “Cross Fertilization: Sustained Delivery and Nanotechnology in Ophthalmology” at an upcoming Formulation and Drug Delivery Committee Meeting of the Massachusetts Biotechnology Council on Wednesday, October 17.

From EyePoint Pharmaceuticals, Inc. 16 Oct 2012

New Wiggler Beamline for X-Ray Synchrotron Footprinting to Probe Protein Structures

Led by a grant from the National Science Foundation (NSF), Mark Chance, PhD, director of the Center for Proteomics and Bioinformatics at Case Western Reserve University School of Medicine, has been awarded $4 million for work with the National Synchrotron Light Source II (NSLS II) at Brookhaven National Laboratory in New York.

15 Oct 2012

Nanomedicine News

Merck Serono to Provide Strategic Support for Auxogyn's Early Embryo Viability Assessment Test

VNT Paclitaxel Nanocarrier-Based Drug Coated Balloon Technology Performs Well in In Vivo Tests

Multi-Functional, NIR Responsive Gold Nanorods for Targeted Delivery of Chemotherapy Drugs

Scientists Determine 3-D Structure of Transcription Initiation Complex

INNI Appoints TAU to Lead Consortium on Nanomedicines for Personalized Theranostics

Novavax Announces Encouraging Clinical Trial Results for Nanoparticle-Based Pandemic Influenza Vaccine

New Nanoparticle-Based Treatment Holds Potential for Traumatic Brain Injury

Novavax Begins Phase 1 Clinical Trial of Nanoparticle-Based RSV Vaccine Candidate

Nanotechnology-Based Delivery System for Sustained Release of Drugs

New Wiggler Beamline for X-Ray Synchrotron Footprinting to Probe Protein Structures

Scientists Create the Largest Atomically Thin Gold Films to Make Electronics Weightless and Invisible

Sustainable Carbon Nanomaterial Gii Set to Transform Energy Storage in Internet of Things Devices

Sustainable Future for Carbon Nanotubes

Sustainable ZnO Nanoparticles for Methylene Blue Cleanup

Enhancing Material Properties through Nanotube Encapsulation

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Conversations on AFM: Applications of BioAFM in Life Science

Sponsored Content

Characterization of Active Pharmaceutical Ingredients, Injectables, and Proteins

The Future of Wound Care: Why Nanofibers are Key to Accelerated Healing

The Evolution of Lipid Nanoparticles

How Emulsion Electrospinning is Transforming Materials